Bioporto ASTHOXF 66 Current Ratio is 3.25 as of Dec. 2025, which is 11% below its 10-year median of 3.65. GuruFocus rates THOXF with a GF Score™ of 66/100 and a GF Value™ of $0.17. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Bioporto AS ranks better than 70.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bioporto AS's current ratio for the quarter that ended in Dec. 2025 was 3.25.
Bioporto AS has a current ratio of 3.25. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Bioporto AS's Current Ratio or its related term are showing as below:
THOXF'
s Current Ratio Range Over the Past 10 Years
Min: 2.32 Med: 3.65 Max: 9.24
Current: 3.25
During the past 13 years, Bioporto AS's highest Current Ratio was 9.24. The lowest was 2.32. And the median was 3.65.
THOXF's Current Ratio is ranked better than 70.56% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs THOXF: 3.25
Bioporto AS (OTCPK:THOXF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bioporto AS Current Ratio Related Terms
Bioporto AS Current Ratio Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Bioporto AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a Current Ratio of 3.25 as of Dec. 2025. This is 11% below median its historical median of 3.65. Over the past decade, Bioporto AS's Current Ratio has ranged from 2.32 to 9.24. According to the industry distribution chart, Bioporto AS ranks #63 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 29.4%.
Is Bioporto AS's Current Ratio too high?
Bioporto AS's current Current Ratio of 3.25 is 11% below median its 10-year median of 3.65. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 9.24. The Medical Diagnostics & Research industry median Current Ratio is 2.06. Bioporto AS's value of 3.25 is 57.8% above this industry median. Based on the distribution chart, Bioporto AS ranks #63 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #63 out of 214 companies for Current Ratio. This puts Bioporto AS in the upper half of its industry. The industry median Current Ratio is 2.06. Bioporto AS's value of 3.25 is 57.8% above this benchmark. Historically, Bioporto AS's own Current Ratio has ranged from 2.32 to 9.24 over the past decade. While the company's 10-year median is 3.65 vs. the industry median of 2.06, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Current Ratio of 3.25 is 57.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Current Ratio is 3.25, which is 11% below median its own 10-year median of 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Current Ratio of 3.25. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 12.4% below its estimated fair value. The current Current Ratio is 3.25, which is 11% below median its 10-year median of 3.65 and 57.8% above the Medical Diagnostics & Research industry median of 2.06. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Current Ratio is 3.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 12.4% below its estimated GF Value™ of $0.17.
Key valuation signals for THOXF:
Current Ratio: 3.25 (11% below median its 10-year median of 3.65)
GF Value™: $0.17 vs. price of $0.15 (12.4% below fair value)
Industry Position: 57.8% above the Medical Diagnostics & Research median (#63 of 214)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for THOXF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
